# Belatacept (Nulojix) in Renal Transplant Recipient With Mild Immunologic Risk Factor: a Pilot Prospective Study.

> **NCT02738918** · PHASE2 · COMPLETED · sponsor: **Assistance Publique - Hôpitaux de Paris** · enrollment: 51 (actual)

## Conditions studied

- Renal Transplant
- Acute Antibody Mediated Rejection
- Mild Immunologic Risk Factor

## Interventions

- **DRUG:** Nulojix (Belatacept)

## Key facts

- **NCT ID:** NCT02738918
- **Lead sponsor:** Assistance Publique - Hôpitaux de Paris
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-12-01
- **Primary completion:** 2017-09-18
- **Final completion:** 2017-09-18
- **Target enrollment:** 51 (ACTUAL)
- **Last updated:** 2019-07-05

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02738918

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02738918, "Belatacept (Nulojix) in Renal Transplant Recipient With Mild Immunologic Risk Factor: a Pilot Prospective Study.". Retrieved via AI Analytics 2026-06-14 from https://api.ai-analytics.org/clinical/NCT02738918. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*